Ramipril-Acrihin, tablets 5 mg 30 pcs

ACE inhibitor, blocks the conversion of angiotensin I to angiotensin II, which results (regardless of plasma renin activity) in a hypotensive effect (in the “lying” and “standing” position of the patient) without a compensatory increase in heart rate. It decreases the production of aldosterone.

Decreases OPPS (post-load), congestion pressure in pulmonary capillaries (preload), resistance in pulmonary vessels; increases IOC and exercise tolerance. Long-term administration of the drug promotes inverse development of myocardial hypertrophy in patients with arterial hypertension and decreases the frequency of arrhythmias during myocardial reperfusion. It improves blood supply of ischemic myocardium and prevents vascular endothelial changes caused by high-cholesterol diet.

Cardioprotective effect of the drug is caused by the influence on the synthesis of prostaglandins, the induction of nitric oxide (NO) formation in endotheliocytes. It activates kallikrein-kinin system, inhibits bradykinin breakdown (increases its concentration), increases Pg synthesis. Enhances coronary and renal blood flow. Decreases platelet aggregation.

Increases tissue sensitivity to insulin, ends fibrinogen synthesis, stimulates synthesis of tissue activator profibrinolysin (plasminogen), promoting thrombolysis.

The onset of hypotensive action of the drug is 1.5 hours after oral administration, maximum effect – after 5-9 hours, the duration of action – 24 hours. There is no withdrawal syndrome.

It reduces mortality in the early and distant periods of myocardial infarction, the rate of recurrent myocardial infarctions and CHD development. Increases survival rate and improves quality of life in patients with CHF.

In patients with congenital and acquired heart disease the drug therapy decreases hypertension in the small circle of circulation if administered for at least 6 months.

In case of portal hypertension it decreases the pressure. Reduces the degree of microalbuminuria (in the initial stage) and the progression of chronic renal failure in patients with severe kidney damage in diabetic nephropathy.

Indications

The drug is indicated in arterial hypertension, malignant and refractory hypertension, vasorenal hypertension, chronic heart failure stages II-III.

The following indications are also: nephropathy against the background of chronic diffuse renal diseases (preclinical and clinical stages), diabetic nephropathy.

Active ingredient

Composition

How to take, the dosage

Interaction

Special Instructions

Contraindications

Side effects

Similarities